Evolving landscape of lung cancer treatment

Figure adapted from Pao, et al. Lancet Oncol 2011

ChemotherapyChemotherapy

± anti-angiogenicsTargeted therapy Cancer immunotherapy

Histological subtype

Molecular pathology (EGFR / ALK / ROS1 / BRAF)

Checkpoint inhibition

NSCLC vs SCLC

1980s 2000s 2015+

Situación en el 2016 del CPNCP estadio IV

ROS1 mutation

Los inicios…

EGFR

Formato taller

Mechanisms of EGFR resistance

ALK

Un año más….

Sequence EGFR mut patients?

EGFR TKI 1st G8-13,7 m

50% T790M=Osimertinib9,6 m

CT 1L=6 mCT 2=3,4 m

CT 1L=6 mCT 2=3,4 m

50% T790M=Osimertinib9,6 m

EGFR TKI 2nd G11-16,6 m

Erlotinib + Bevacizumab16 m

Resistance? OS data?

Osimertinib19 m

Resistance?OS data?

Volvemos a una tarde

Id reservando lugar en la agenda…